SLC5A2 and type 2 diabetes mellitus: Dapagliflozin (DAPA) and empagliflozin (EMPA) are potent, competitive, and reversible human SGLT2 inhibitors, used mainly for the therapy of type 2 diabetes (T2D) [3].